Literature DB >> 14697724

Performance of a dual-chamber implantable defibrillator algorithm for discrimination of ventricular from supraventricular tachycardia.

Claude Kouakam1, Salem Kacet, Jean-René Hazard, Ange Ferraci, Hassan Mansour, Pascal Defaye, Jean-Marc Davy, Marie Lambiez.   

Abstract

BACKGROUND: Inappropriate therapies remain a major problem in patients with implantable cardioverter defibrillators (ICDs). Decreasing the proportion of inappropriate therapies is a major objective. With the addition of atrial detection and advanced algorithms, dual-chamber ICDs are designed to offer better discrimination of ventricular (VT) and supraventricular (SVT) arrhythmias. The present multicentre, open study aimed to evaluate the performance of a dual-chamber detection algorithm, the Atrial View algorithm, incorporated in a dual-chamber ICD, the Ventak AV (Guidant Inc., St. Paul, Minnesota, USA). METHODS AND
RESULTS: Fifty-one patients (45 males, 62+/-11 years, ejection fraction 42+/-15%) with standard indications received a Ventak AV ICD which analyzes, within the VT zone RR stability, tachycardia onset, atrial rate and AV relationship. Predischarge enhanced-detection algorithms were prospectively programmed: stability 24 ms, onset 9%, atrial fibrillation threshold 200 beats/min, and Vrate>Arate. An additional sustained rate duration criterion was programmed at least at 30 s. ICDs were interrogated every 3 months or when patients received shocks. A blinded review of electrograms for arrhythmia diagnosis and appropriateness of therapy was performed by 2 experts. Over the follow-up period (12+/-3.6 months), a total of 400 tachycardia episodes was recorded within the VT zone. After the review of stored electrograms, 237 (59%) true positive, 143 (36%) true negative, 17 (4%) false positive and 3 (1%) false negative episodes were diagnosed. Considering the 3 VTs incorrectly detected by the detection algorithms, therapy was delivered in 2 cases after sustained rate duration and 1 VT reverted spontaneously. Inappropriate therapy occurred in 17 cases. All but 1 were related to SVT with 1:1 atrioventricular relationship. Finally, on a per episode basis, the detection algorithm sensitivity was 99% and specificity was 89%.
CONCLUSIONS: Programming of detection criteria based on stability, onset, atrial fibrillation rate threshold and Vrate>Arate allows a 99% sensitivity and an 89% specificity in Guidant ICDs. Discrimination of SVT with 1:1 atrioventricular relationship, however, remains a challenge for which new algorithms have to be designed.

Entities:  

Mesh:

Year:  2004        PMID: 14697724     DOI: 10.1016/j.eupc.2003.09.007

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  5 in total

1.  Case report: Delayed detection of ventricular tachycardia due to intradevice interactions by implantable atrio-ventricular pacer/cardioverter defibrillator.

Authors:  Bharat K Kantharia; Farooq A Padder
Journal:  J Interv Card Electrophysiol       Date:  2006-10-03       Impact factor: 1.900

2.  Does the rate of inappropriate therapy differ in implantable cardioverter-defibrillators from different manufacturers?

Authors:  Arash Arya; Majid Haghjoo; Zahra Emkanjoo; Mohammad Reza Dehghani; Mohammad Ali Sadr-Ameli
Journal:  J Interv Card Electrophysiol       Date:  2007-01-17       Impact factor: 1.900

3.  [Stored electrograms in pacemakers and ICDs from Boston Scientific].

Authors:  A Schaumann; C W Israel
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2010-03

4.  Reduction of the inappropriate ICD therapies by implementing a new fuzzy logic-based diagnostic algorithm.

Authors:  Michał Lewandowski; Andrzej Przybylski; Wiesław Kuźmicz; Hanna Szwed
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-09       Impact factor: 1.468

5.  The use of implantable cardioverter defibrillators in Iceland: a retrospective population based study.

Authors:  Margret Leosdottir; Gudrun Reimarsdottir; Gizur Gottskalksson; Bjarni Torfason; Margret Vigfusdottir; David O Arnar
Journal:  BMC Cardiovasc Disord       Date:  2006-05-24       Impact factor: 2.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.